Capricor Therapeutics (NASDAQ:CAPR) shares tumble 67% after FDA raises concerns over Deramiocel data
Shares of Capricor Therapeutics, Inc. fell by nearly two-thirds on Monday after U.S. regulators raised concerns over the efficacy data for deramiocel, the company’s treatment aimed at Duchenne muscular dystrophy.
